Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Recruiting 2

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 7Genitourinary 5Breast 4Thoracic 3Gynecologic 3Sarcoma 2Endocrine 2CNS 2Other solid neoplasm 1NET 1Head & Neck 1

Conditions

Glioblastoma 8Brain Neoplasms 8Breast Neoplasms 4Urinary Bladder Neoplasms 3Thyroid Neoplasms 3Ovarian Neoplasms 3Neuroendocrine Tumors 3Neoplasm Metastasis 3Glioma 3Cholangiocarcinoma 3Carcinoma, Hepatocellular 3Uterine Cervical Neoplasms 2Testicular Neoplasms 2Stomach Neoplasms 2Spinal Cord Neoplasms 2Small Cell Lung Carcinoma 2Sarcoma 2Salivary Gland Neoplasms 2Prostatic Neoplasms 2Pheochromocytoma 2Paraganglioma 2Pancreatic Neoplasms 2Neoplasms 2Meningioma 2Lung Neoplasms 2Gliosarcoma 2Carcinoma, Transitional Cell 2Astrocytoma 2Adrenal Gland Neoplasms 2Vaginal Neoplasms 1

Interventions

pembrolizumab 5Docetaxel 4ulixertinib 2Trastuzumab 2Radiotherapy 2Paclitaxel 2Oxaliplatin 2Nivolumab 2Magnetic Resonance Spectroscopy 2Leucovorin 2Irinotecan 2Fluorodeoxyglucose F18 2Carboplatin 2Capecitabine 2Bevacizumab 2trastuzumab biosimilar HLX02 1trametinib 1tipifarnib 1temsirolimus 1tanespimycin 1spartalizumab 1sonidegib 1sargramostim 1sapanisertib 1relatlimab 1regorafenib 1pertuzumab 1palbociclib 1osimertinib 1omipalisib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Stomach Neoplasms × Fluorodeoxyglucose F18 × CNS × Clear all
NCT06503146 2026-05-19

18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection

National Institutes of Health Clinical Center (CC)

Phase 2 Recruiting
320 enrolled
CNSEndocrineGastrointestinalGenitourinaryGynecologicOther solid neoplasmSarcomaThoracic

Urinary Bladder Neoplasms, Carcinoma, Hepatocellular, Mesothelioma, Ovarian Neoplasms, Paraganglioma, Pheochromocytoma, Sarcoma, Stomach Neoplasms, Cholangiocarcinoma, Small Cell Lung Carcinoma

NCT07118176 2025-08-12

Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers

Jonsson Comprehensive Cancer Center

Phase 1 Recruiting
30 enrolled
BreastCNSEndocrineGastrointestinalGenitourinaryGynecologicHead & NeckNETSarcomaThoracic

Adrenal Gland Neoplasms, Anus Neoplasms, Urinary Bladder Neoplasms, Brain Neoplasms, Breast Neoplasms, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Carcinoma, Hepatocellular, Lung Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Penile Neoplasms, Prostatic Neoplasms, Salivary Gland Neoplasms, Sarcoma, Stomach Neoplasms, Testicular Neoplasms, Thyroid Neoplasms, Uterine Neoplasms, Vaginal Neoplasms, Colorectal Neoplasms, Carcinoma, Medullary, Cholangiocarcinoma, Neuroendocrine Tumors, Solitary Fibrous Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡